Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

European Respiratory Journal

Volumn 41, Issue 6, 2013, Pages 1393-1400

  Skripconoka, Vija ^a   Danilovits, Manfred ^b   Pehme, Lea ^b   Tomson, Tarmo ^c   Skenders, Girts ^a   Kummik, Tiina ^b   Cirule, Andra ^a   Leimane, Vaira ^a   Kurve, Anu ^c   Levina, Klavdia ^c   Geiter, Lawrence J ^d   Manissero, Davide ^e   Wells, Charles D ^d  

^a RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^b TARTU UNIVERSITY CLINICS   (Estonia)

^c North Estonia Medical Centre   (Estonia)

^d Otsuka Pharmaceutical Development and Commercialization   (United States)

^e Otsuka SA   (Switzerland)

Author keywords

Extensively drug resistant; Mycobacterium; Pulmonary infection; Treatment outcomes

Indexed keywords

DELAMANID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; ADOLESCENT; DRUG ADMINISTRATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; OXAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84878776777     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00125812     Document Type: Article

References (30)

1. World Health Organization. Towards Universal Access to Diagnosis and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis by 2015: WHO Progress Report 2011. Geneva, World Health Organization, 2011.
2. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
3. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
4. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012; 40: 9-11.
5. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
6. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
7. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
8. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659. (Pubitemid 46780649)
9. Kurbatova EV, Taylor A, Gammino VM, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) 2012; 92: 397-403.
10. Manissero D, Hollo V, Huitric E, et al. Analysis of tuberculosis treatment outcomes in the European Union and European Economic Area: efforts needed towards optimal case management and control. Euro Surveill 2010; 15: pii 19514.
11. European Centre for Disease Prevention and Control/WHO Regional Office for Europe: Tuberculosis surveillance in Europe 2008. Stockholm, European Centre for Disease Prevention and Control, 2010.
12. van Hest R, Ködmön C, Verver S, et al. Tuberculosis treatment outcome monitoring in European Union countries: systematic review. Eur Respir J 2013; 41: 635-643.
13. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
14. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
15. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
16. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
17. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954.
18. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
19. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, World Health Organization, 2008.
20. Gammino VM, Taylor AB, Rich ML, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011; 15: 1315-1322.
21. International Conference on Harmonisation of Technical Requirements of Registration for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice, E6 (R1). 1996.
22. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. www. wma.net/en/30publications/ 10policies/b3/ Date last accessed: August 7, 2012.
23. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279. (Pubitemid 29481843)
24. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
25. Zumla A, Blasi F, Raviglione M. Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance. Eur Respir J 2012; 39: 802-804.
26. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: imperative for chest physicians. Eur Respir J 2011; 37: 978-981.
27. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
28. van der Werf MJ, Langendam MW, Huitric E, et al. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012; 39: 1511-1519.
29. Migliori GB, Sotgiu G. Treatment of tuberculosis: have we turned the corner? Lancet 2012; 380: 955-957.
30. D'Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med 2012; 367: 2154; author reply 2155-6.